Rx Product News (March 2017)

Pharmacy Times, March 2017 Central Nervous System, Volume 83, Issue 3

Read about the new Rx products featured in March.

RHOFADEMARKETED BY: Allergan

INDICATION: Allergan has announced the FDA approval of Rhofade cream, which is indicated for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

DOSAGE FORM: Topical cream: once-daily application

FOR MORE INFORMATION: allergan.com

NARCAN NASAL SPRAYMARKETED BY: Adapt Pharma

INDICATION: The FDA has approved Narcan Nasal Spray (concentrated naloxone) as a 2-mg formulation for the emergency treatment of known or suspected opioid abuse, as manifested by respiratory and/or central nervous system depression.

DOSAGE FORM: Nasal spray: 2 and 4 mg

FOR MORE INFORMATION: adaptpharma.com

LINZESSMARKETED BY: Ironwood and Allergan

INDICATION: The FDA has approved a 72-mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients. Linzess is now approved in 3 dosage strengths: 290 mcg for adult patients with irritable bowel syndrome with constipation, and 145 mcg and the new 72 mcg for adults with CIC.

DOSAGE FORM: Capsules: 72, 145, and 290 mcg

FOR MORE INFORMATION: allergan.com

EMFLAZAMARKETED BY: Marathon Pharmaceuticals, LLC

INDICATION: The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of Duchenne muscular dystrophy in patients 5 years and older.

DOSAGE FORM: Tablets (6, 18, 30, and 36 mg) and oral suspension (22.75 mg/mL)

FOR MORE INFORMATION: emflaza.com